Aethlon Medical Inc. (NASDAQ:AEMD) shares are dropping Friday, pulling back after the stock surged more than 300% the previous day.
- Aethlon Medical stock is among today’s weakest performers. Why is AEMD stock dropping?
A Quick Recap of Thursday’s Merger News
Aethlon shares exploded higher Thursday after the company agreed to merge with North Immunology in an all-stock deal, forming a combined business that will trade on Nasdaq under the ticker NRTX. Backed by a $180 million private placement, the newly combined company will focus on advancing North Immunology’s lead drug candidate, NOR-101, aimed at treating inflammatory and immune conditions.
Existing Aethlon shareholders will hold a small slice, roughly 4.75%, of the combined company once the deal closes, with North Immunology investors controlling the rest. Legacy Aethlon holders will also receive contingent rights tied to any future value extracted from Aethlon’s existing Hemopurifier device business.
The combined company carries a pro forma valuation near $346.5 million, and the deal still needs shareholder and regulatory sign-off before an expected close in early 2027.
Today’s Pullback Follows a Historic One-Day Surge
That kind of one-day move rarely holds entirely, and today’s session is proving no exception. Shares are cooling off after more than quadrupling in Thursday’s session, a move so dramatic that some retracement was widely expected.
Rapid, outsized rallies like this one often trigger profit-taking almost immediately afterward, as early buyers lock in gains and the stock searches for a steadier trading range while investors digest exactly what the merger means heading into its expected close next year.
AEMD Shares Are Tumbling
AEMD Price Action: Aethlon shares were down 9.29% at $6.15 at the time of publication on Friday, according to Benzinga Pro.
Image: Zakharchuk/Shutterstock
Login to comment